BiotechTube

HSK21542 tablet + Placebo

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pruritus

Conditions

Pruritus

Trial Timeline

Mar 8, 2024 → Apr 11, 2025

NCT ID
NCT06290375

About HSK21542 tablet + Placebo

HSK21542 tablet + Placebo is a phase 2 stage product being developed by Haisco Pharmaceutical Group for Pruritus. The current trial status is unknown. This product is registered under clinical trial identifier NCT06290375. Target conditions include Pruritus.

What happened to similar drugs?

0 of 6 similar drugs in Pruritus were approved

Approved (0) Terminated (1) Active (5)
🔄MR13A9 + PlaceboKissei PharmaceuticalPhase 3
🔄Dupilumab + Placebo + Fexofenadine (loratadine if not available)SanofiPhase 3
🔄HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
❌5 mg Serlopitant TabletsVyne TherapeuticsPhase 3
🔄5mg Serlopitant Tablets + Placebo TabletsVyne TherapeuticsPhase 3
🔄5mg Serlopitant Tablets + Placebo TabletsVyne TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06290375Phase 2UNKNOWN

Competing Products

20 competing products in Pruritus

See all competitors
ProductCompanyStageHype Score
Nalmefene + PlaceboTharimmunePhase 2
32
SHR0410Jiangsu Hengrui MedicinePhase 1
29
SHR0410 + PlaceboJiangsu Hengrui MedicinePhase 1
25
DNK333 5 mg + Placebo to 5 mg + DNK333 25 mg + Placebo to 25 mg + DNK333 100 mg + Placebo to 100 mg + Betamethasone 4 mg + DNK333 1mg + Placebo to 1mgNovartisPhase 2
35
MR13A9 + PlaceboKissei PharmaceuticalPhase 3
40
MR13A9 + PlaceboKissei PharmaceuticalPhase 2
35
GabapentinPfizerPre-clinical
22
Dupilumab + Placebo + Fexofenadine (loratadine if not available)SanofiPhase 3
47
BLU-5937 + PlaceboGSK plcPhase 2
35
Dupilumab 300Mg Solution for InjectionRegeneron PharmaceuticalsPhase 2
35
REGN846Regeneron PharmaceuticalsPhase 1/2
24
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 2
35
Stage I:HSK21542 0.05 μg/kg + Stage I:HSK21542 0.15 μg/kg + Stage I:HSK21542 0.30 μg/kg + Stage I:HSK21542 0.80 μg/kg + Stage II:HSK21542 0.3 μg/kg + Stage II:HSK21542 0.6 μg/kgHaisco Pharmaceutical GroupPhase 2
35
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
40
nalbuphine HCl ERTrevi TherapeuticsPhase 2/3
32
Nalbuphine HCL ERTrevi TherapeuticsPhase 1
23
nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BIDTrevi TherapeuticsPhase 2/3
32
VLY-686 + PlaceboVanda PharmaceuticalsPhase 2
25
VLY-686 + PlaceboVanda PharmaceuticalsPhase 1
19
Serlopitant + PlaceboVyne TherapeuticsPhase 2
17